Orchestra BioMed Holdings (OBIO) Cash & Current Investments (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Cash & Current Investments for 7 consecutive years, with $94.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 89.24% year-over-year to $94.4 million; the TTM figure through Mar 2026 stood at $94.4 million (up 89.24% YoY), while the FY2025 annual figure was $156.4 million, up 54.35% from the prior year.
• Cash & Current Investments fell to $94.4 million in Q1 2026 per OBIO's latest filing, from $156.4 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $215.9 million in Q2 2023 and bottomed at $735217.0 in Q3 2022.
• Historically, Cash & Current Investments has averaged $74.5 million across 5 years, with a median of $87.5 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Current Investments soared 16418.84% — and 2024, when it plunged 81.64%.
• Orchestra BioMed Holdings' Cash & Current Investments stood at $19.9 million in 2022, then soared by 340.5% to $87.5 million in 2023, then grew by 15.79% to $101.4 million in 2024, then soared by 54.35% to $156.4 million in 2025, then slumped by 39.65% to $94.4 million in 2026.
• Business Quant data shows OBIO's Cash & Current Investments at $94.4 million in Q1 2026, $156.4 million in Q4 2025, and $95.8 million in Q3 2025.